Parigi, 10 febbraio, 2010 - Deinove, societ? biotech specializzata nella ricerca e nello sviluppo di processi innovativi per la produzione di biocombustibile, ? stata selezionata per partecipare a CleanEquity Monaco 2010, la vetrina pi? importante per le aziende che operano nel settore delle tecnologie pulite ed ecologiche (Cleantech) di nuova generazione. La conferenza si terr? il 4 e 5 marzo allo Sporting d'Hiver di Monaco.

Jacques Biton, CEO of Deinove, will be presenting on Thursday March, 4th to invited industry-specific financial and strategic investors, policy makers, legislators and media.

Innovator Capital, London specialist investment bank, hosts the annual invitation-only event. CleanEquity Monaco's regional host is the Monaco Chamber of Economic Development. Other local partners include Prince Albert II of Monaco's Foundation, the Monte Carlo SBM, and the Stelios Philanthropic Foundation. Collaborators for the 2010 event include Arup, Covington and Burling LLP, the Hugin Group, Invest Securities, Royal Philips Electronics NV and the UNEP Fi.

"Deinove is pleased to present its recent development and corporate strategy at the world-renowned CleanEquity Monaco 2010. This would be a great opportunity for us to present our breakthrough industrial microbial processes for the production of 2nd-generation biofuels, chemical commodities and compounds of industrial interest using Deinococcus and other radio-resistant bacteria", emphasized Deinove CEO Jacques Biton.

About Deinove

Deinove was incorporated in late 2006 under the joint impetus of Philippe Pouletty MD (Managing Partner at the private equity firm Truffle Capital) and Miroslav Radman PhD (Professor of Cell Biology at Paris-Descartes University, a member of the French Academy of Science and winner of the 2003 INSERM Prize for Medical Research). Professor Radman elucidated and patented the genetic mechanism behind the extraordinary biodiversity and robustness of the bacterium Deinococcus, on which Deinove's innovative strategy is based.

Deinove is dedicated to the development and commercial exploitation of innovative technological processes for the production of biofuels and other compounds of industrial or pharmaceutical interest by exploiting the Deinococci's exceptional natural properties. Deinove intends to leverage its proprietary bacteria, technologies and processes by outlicensing to industrial partners.

Deinove has forged several strong collaborations with leading academic laboratories at Paris-Descartes University (Miroslav Radman and Ivan Matic), IGS-CNRS Marseille (Jean-Michel Claverie), CPBS CNRS-University of Montpellier (Jean-Paul Leonetti) and INSA Toulouse (Carole Jouve and G?rard Goma).

To date, Deinove has received a total of E3.4 million in equity investment from Truffle Capital and received E8.9 million in funding (including E6 million for Deinove) from the French government's Strategic Industrial Innovation programme. The other project partners are Tereos (Europe's leading bioethanol producer), its BENP Lillebonne and Syral subsidiaries and two academic labs. The DEINOL project's goal is to pioneer ways of producing lignocellulosic ("second-generation") ethanol in existing industrial installations and without the need for massive additional investment.

Deinove currently employs 14 staff. The company is headquartered in Paris and operates laboratory facilities at the Cap Alpha technology park in Montpellier, as part of its collaborative work with expert academic labs.

Press contacts

ALIZE RP
Caroline Carmagnol
Tel.: +33 (0)6 64 18 99 59
caroline@alizerp.com

Charles Catherinot
Tel.: +33 (0)1 42 68 86 40
charles@alizerp.com

Juliette Vandenbroucque
Tel.: +33 (0)1 42 68 86 40
Juliette@alizerp.com

Deinove
Angelita de Francisco
Business Development
Tel.: +33 (0)6 07 15 28 87
angelita@deinove.com



Copyright Hugin

Questo comunicato ? distribuito da Hugin. L'emittente ? l'unico responsabile per il contenuto del comunicato.

[CN#162936]